Gazyva/Gazyvaro is an engineered monoclonal antibody designed to attach to CD20, a protein expressed on certain B cells, but not on stem cells or plasma cells. Gazyva/Gazyvaro is designed to attack and destroy targeted B-cells both directly and together with the body's immune system. Gazyva is marketed as Gazyvaro in the EU and Switzerland.
Gazyva/Gazyvaro is currently approved in more than 90 countries in combination with chlorambucil for people with previously untreated chronic lymphocytic leukaemia, in more than 80 countries in combination with bendamustine for people with certain types of previously treated follicular lymphoma, and in more than 70 countries in combination with chemotherapy for previously untreated follicular lymphoma.
In late 2021/early 2022, the United States, Europe and many other countries approved a new, shorter duration infusion of Gazyva/Gazyvaro, meaning the treatment can be administered to the patient over a shorter time period and can result in potential time savings for patients, as the standard rate of infusion can take approximately three to five hours.